A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2019
At a glance
- Drugs Binimetinib (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms NEMO
- Sponsors Array BioPharma; Novartis
- 05 Jul 2019 This trial has been completed in Greece (on 2019-06-04).
- 05 Jul 2019 This trial has been completed in Hungary (on-2019-06-04).
- 04 Jul 2019 This trial has been completed in Belgium (on 2019-06-04).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History